Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VIR-7831 · 1 trial · 1 indication
COVID-19 progression defined as hospitalization \>24 hours or death
| Arm | Type | Description |
|---|---|---|
| VIR-7831 (Sotrovimab) | EXPERIMENTAL | Participants received 500 mg sotrovimab administered intravenously (IV) |
| Placebo | PLACEBO_COMPARATOR | Participants received placebo administered intravenously (IV) |
| Name | Type | Description |
|---|---|---|
| VIR-7831 (sotrovimab) | BIOLOGICAL | VIR-7831 (sotrovimab) given by intravenous infusion (single dose) |
| Placebo | DRUG | Sterile normal saline (0.9% NaCl) given by intravenous infusion (single dose) |
Inclusion Criteria: * Participant must be aged 18 years or older AND at high risk of progression of COVID-19 or ≥ 55 years old * Participants must have a positive SARS-CoV-2 test result and oxygen saturation ≥94% on room air and have COVID-19 symptoms and be less than or equal to 5 days from onset ...
VIR-7831 is an investigational monoclonal antibody being studied for the treatment of COVID-19. It is being developed for use in outpatients with early COVID-19 infection. The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
VIR-7831 is a monoclonal antibody designed to target the SARS-CoV-2 virus, which causes COVID-19. As an antibody, it works by binding to the virus to neutralize it and prevent it from infecting human cells. This mechanism is intended to reduce the severity and duration of COVID-19 illness.
VIR-7831 is being developed by Vir Biotechnology, Inc., a company traded on the NASDAQ under the ticker symbol VIR. The company is focused on infectious disease treatments and is advancing this monoclonal antibody through clinical trials for COVID-19.
VIR-7831 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The drug is being evaluated in clinical trials to assess its safety and efficacy for treating COVID-19 in outpatient settings.
VIR-7831 has been studied in one completed Phase 2 clinical trial, identified as NCT04545060. This trial, titled 'VIR-7831 for the Early Treatment of COVID-19 in Outpatients,' enrolled 1,057 participants across multiple countries including the United States, Brazil, Canada, and the United Kingdom. The trial was randomized, double-blind, and placebo-controlled.
VIR-7831 is also known as sotrovimab. The drug is a monoclonal antibody developed by Vir Biotechnology for the treatment of COVID-19. It has been studied under the name VIR-7831 in clinical trials, and sotrovimab is the alternative name used for the same investigational therapy.